Endovascular Engineering, Inc.

Endovascular Engineering, Inc. (E2) is a clinical-stage medical device company based in Menlo Park, California, specializing in advanced mechanical thrombectomy solutions for venous thromboembolism (VTE), including pulmonary embolism (PE) and deep vein thrombosis (DVT). Founded in 2019 by Dr. Luis Savastano and backed by approximately $42 million in venture funding, E2 has developed the Hēlo™ PE Thrombectomy System—a minimally invasive catheter-based device designed to safely and effectively remove blood clots from the lungs. The Hēlo system features a unique self-expanding funnel design that delivers large-bore clot engagement through a small-profile catheter, reducing vascular trauma and hemodynamic compromise. Its dual-action technology combines high-speed mechanical agitation with simultaneous physician-controlled aspiration for single-pass clot disruption and removal. The system received FDA Investigational Device Exemption approval in January 2024 and is currently in pivotal clinical trials. E2 targets underserved peripheral VTE indications and aims to redefine the standard of care in endovascular thrombectomy.